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A B S T R A C T   
An important motivation for the use of nanomaterials and nanoarchitectures in cancer therapy emanates from 
the widespread emergence of drug resistance. Although doxorubicin (DOX) induces cell cycle arrest and DNA 
damage by suppressing topoisomerase activity, resistance to DOX has severely restricted its anti-cancer potential. 
Hyaluronic acid (HA) has been extensively utilized for synthesizing nanoparticles as it interacts with CD44 
expressed on the surface of cancer cells. Cancer cells can take up HA-modified nanoparticles through receptor- 
mediated endocytosis. Various types of nanostructures such as carbon nanomaterials, lipid nanoparticles and 
polymeric nanocarriers have been modified with HA to enhance the delivery of DOX to cancer cells. Hyaluronic 
acid-based advanced materials provide a platform for the co-delivery of genes and drugs along with DOX to 
enhance the efficacy of anti-cancer therapy and overcome chemoresistance. In the present review, the potential 
methods and application of HA-modified nanostructures for DOX delivery in anti-cancer therapy are discussed.   
1. Introduction 
Different strategies are currently utilized in anti-cancer treatment, 
including surgery, chemotherapy, targeted therapy, radiotherapy and 
immunotherapy. Surgery is commonly conducted for early-stage and 
less aggressive tumors, but is not very useful for advanced metastatic 
tumors. Chemotherapy is one of the most common methods used to kill 
cancer cells and treat advanced tumors (Ashrafizadeh, Najafi, Makvandi, 
et al., 2020; Bagheri et al., 2020; Khatami et al., 2021; Poh et al., 2019). 
Chemotherapy is preferred over surgery because of its non-invasive or 
minimally-invasive nature. Accordingly, an extensive array of chemo-
therapeutic agents such as cisplatin, paclitaxel, docetaxel and doxoru-
bicin (DOX) have been developed for cancer chemotherapy (Abu 
Samaan et al., 2019; Ashrafizadeh, Zarrabi, Hashemi, et al., 2020a; 
Ashrafizadeh, Zarrabi, Hashemi, et al., 2020b; Ashrafizadeh, Zarrabi, 
Hushmandi, et al., 2020; Clarke et al., 2019; Dai et al., 2016; Li, Zhan, 
et al., 2019; Swamy et al., 2017; Zhang, Sui, et al., 2020). Nevertheless, 
the aforementioned chemotherapeutic agents have not been completely 
successful in clinical studies. Several important questions arise 
regarding treatment failure. For instance, in the treatment of brain tu-
mors, blood-brain barrier (BBB) prevents the entry of chemotherapeutic 
drugs to the brain (Arvanitis et al., 2020). Cancer cells also form a blood- 
tumor barrier (BTB) that restricts the penetration of anti-cancer drugs 
into tumor tissues (Chen, Zeng, et al., 2019). Anti-tumor agents often 
suffer from poor bioavailability. High doses of these chemotherapeutic 
agents are often undesirable because of their concentration-dependent 
toxicity (Ashrafizadeh, Zarrabi, Hashemi, et al., 2020a; Ashrafizadeh, 
Zarrabi, Hashemi, et al., 2020b; Varela-López et al., 2019). More 
importantly, the frequent application of chemotherapeutic drugs often 
results in the emergence of a phenomenon known as “drug-resistance” 
(Abd-Rabou et al., 2020; Manu et al., 2014; Manu et al., 2015; Poh et al., 
2019). 
Over the last couple of decades, scientists have been actively 
searching for additional methods to improve the efficacy of cancer 
chemotherapy. Much effort has been devoted to increase the anti-tumor 
activity of chemotherapeutic agents (Manu et al., 2012; Rajendran, Ong, 
et al., 2011). Taking into consideration the difficulties associated with 
cancer chemotherapy such as chemoresistance, poor bioavailability and 
presence of the BBB and BTB, it appears that nanotechnology may be a 
viable option for improving the efficacy of cancer chemotherapy. 
Increasing evidence demonstrates the potential of nanostructures in 
enhancing the bioavailability of anti-cancer agents, enabling targeted 
delivery and allowing penetration into BBB and BTB (Curley et al., 2020; 
Le Floc'h et al., 2020). Nanoparticles may be modified by other agents to 
promote their targeted delivery (Chiesa et al., 2018; Lu, Luo, et al., 2020; 
Naserifar et al., 2020). 
In the present review, we focus on delivery of DOX using hyaluronic 
acid (HA)-modified nanostructures. The reason for choosing DOX is its 
wide application in cancer treatment and frequency of resistance that 
novel strategies should be deployed in this case. Furthermore, among 
anthracycline members, DOX application in cancer therapy in more 
common compared to daunorubicin, epirubicin, idarubicin, mitoxan-
trone and valrubicin. Therefore, we allotted this review to investigating 
potential application of HA-modified nanostructures in DOX delivery. 
Overall, we first introduce chemistry and biology of HA. This will be 
followed by discussion on the application of DOX in anti-cancer therapy 
and review of its mechanisms of resistance. HA-based functionalized 
materials designed for DOX delivery, co-delivery of DOX with genes or 
anti-tumor drugs, including their applications in theranostic will then be 
critically analyzed. 
2. Structure and properties of HA: chemistry and biology 
2.1. Chemistry aspect 
HA is a natural linear polysaccharide consisting of D-glucuronic acid 
and N-acetyl-D-glucosamine units (Fig. 1) (Cai et al., 2019; Luo et al., 
2019; Zhai et al., 2020). This polysaccharide was first isolated from the 
bovine eye in 1934, and its molecular weight is dependent on the length 
of the chains (Wickens et al., 2017). HA is a hydrophilic polysaccharide 
and attracts moisture due to the abundant presence of hydroxyl groups. 
It can bind to water molecules via hydrogen bonds. The functional 
groups on HA such as carboxyl, hydroxyl, and acetamido can be 
employed for chemical modification (Zuber et al., 2011). For example, 
researchers have developed HA derivatives including dopamine-HA 
(Texidó et al., 2017) and methacrylate-HA (Gwon et al., 2017) with 
diverse biomedical applications. As an anionic polysaccharide, HA is 
biodegradable and biocompatible, leading to significant applications in 
biomedicine (Choi et al., 2012). 
HA is the main component of the extracellular matrix (ECM) exclu-
sively found in skin, synovial fluid, and vitreous humor (Fig. 1) (Lee & 
Spicer, 2000). While a variety of sources including animal tissues, mi-
crobial production systems or synthetic enzymatic reactions have been 
deployed for the preparation of HA, commercial HA is commonly ob-
tained from animal sources (Liu et al., 2011; Sze et al., 2016). Depro-
tonation of the functional groups of HA occurs under physiological 
conditions due to the pKa = 3–4 of the carboxyl groups of HA (Huang & 
Huang, 2018). HA is a hydrophilic agent and can form viscous and 
elastic gels by binding to water (Payne et al., 2018). Membrane-bound 
HA synthase enzymes are responsible for the biosynthesis of HA, and 
the resulting HA can have a molecular weight in the range of 5–20,000 
kDa (Cowman & Matsuoka, 2005; Itano et al., 1999). 
2.2. Biological aspect 
HA nanoparticles are valuable candidates in the field of biomedicine. 
There are reactive sites on the HA molecule, including carboxylic 
groups, hydroxyl groups, and -NHCOCH3 groups that have the potential 
for covalent modification; carboxylic group can be used for chemical 
modification by amination or esterification (Jiang et al., 2019; Liu, 
Liang, et al., 2020). HA-based nanoscale delivery systems have been 
extensively applied in cancer therapy due to the affinity of HA in binding 
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to CD44 molecules expressed on the surface of cancer cells (Kim et al., 
2019). CD44 is a multifunctional cell surface glycoprotein involved in 
the proliferation, migration and angiogenesis. Recently, selenium and 
dopamine-crosslinked HA hydrogels were prepared for breast cancer 
chemotherapy. Selenium is capable of triggering dopamine polymeri-
zation by providing an alkaline pH and interacting with functional 
groups of HA, and can inhibit cancer proliferation and survival via a pro- 
oxidant effect (Yang, Lee, et al., 2020). HA-modified selenium nano-
particles have been applied for the delivery of paclitaxel in cancer 
therapy. HA enables targeted delivery and cellular uptake by lung can-
cer cells via clathrin-mediated endocytosis. Suppression of proliferation 
and invasion has been observed following treatment with HA-modified 
selenium nanoparticles (Zou et al., 2019). The benefits of HA nano-
particles are their stability and biocompatibility (Xu et al., 2020). HA 
nanoparticles are internalized into cells due to their binding to CD44, 
making them potential candidates to suppress cancer progression 
(Wang, Liu, et al., 2020). 
3. Cancer resistance mechanisms: DOX and role of HA 
3.1. Doxorubicin and resistance mechanisms 
DOX is an anthracycline antibiotic with brand name Adriamycin, 
which is extensively deployed in the treatment of different hematolog-
ical and solid tumors (Ashrafizaveh et al., 2021; Mohajeri & Sahebkar, 
2018). DOX is isolated from Streptomyces peucetius, and structurally, 
DOX possesses an amino sugar and four rings typical of an anthraqui-
none structure (Chao Chen, Lu, et al., 2018). The major anti-cancer 
mechanisms of DOX, include the suppression of topoisomerase II ac-
tivity and intercalation with DNA thus preventing cell replication and 
enhancing generation of free radicals (Meredith & Dass, 2016). DOX is 
popular in cancer therapy due to its low cost and diverse applications to 
various types of cancers (Rajendran et al., 2012; Rajendran, Li, et al., 
2011; Shishodia et al., 2007). However, the benefits of DOX adminis-
tration are limited due to the development of resistance in cancer cells 
(Zhang, Zhou, et al., 2019). Consequently, different approaches such as 
changing the type of chemotherapy delivery route, combination therapy 
with other anti-tumor agents, gene therapy and the use of nanocarriers 
have been proposed for improving the efficacy of DOX in cancer therapy 
(Guo et al., 2020; Wang, Luo, et al., 2019; Yang, Li, et al., 2020). 
It appears that the reduced intracellular accumulation of DOX in 
cancer cells is also responsible for developing DOX resistance. The anti- 
tumor agents such as imatinib, curcumin and canagliflozin are capable 
of promoting DOX sensitivity via down-regulation of the P-gp as a drug 
efflux pump, and enhancing the cellular uptake of DOX (Chen, Liu, et al., 
2019; Yang, Li, et al., 2020; Zhong et al., 2020). Cancer stem cells (CSCs) 
are considered as potential targets in cancer therapy, as they can 
participate in chemoresistance and aggressive behavior of cancers (Duan 
et al., 2021). DOX administration eradicates non-side population of 
thyroid cancer cells that is beneficial for CSCs as they can grow easily 
and without competition. Noteworthy, CSCs are able to induce DOX 
resistance via upregulation of drug transporters such as MDR1 and/or 
ABCG2 (Zheng et al., 2010). Non-coding RNAs (ncRNAs), especially 
microRNAs (miRNAs) play a significant role in triggering DOX resis-
tance. For instance, exosome-mediated delivery of miRNA-223 to gastric 
cancer cells mediates their DOX resistance via F-box and WD repeat 
domain-containing 7 (FBXW7) down-regulation (Gao et al., 2020). Be-
sides, miRNA-21 induces DOX resistance in prostate cancer cells (PC3 
cells) via down-regulation of phosphatase and tensin homolog (PTEN) as 
a tumor-suppressor factor (Zhao et al., 2021). 
Nanoparticles are promising candidates for enhancing the anti-tumor 
activity of DOX against cancer cells and preventing chemoresistance 
(Coelho et al., 2019; Pishavar et al., 2019; Zhang, Jia, et al., 2019). 
Increasing DOX internalization in cancer cells, reducing IC50 value of 
DOX and co-delivery option are benefits of using nanoparticles for DOX 
delivery in cancer suppression (Ashrafizadeh, Zarrabi, Hashemi, et al., 
2020a; Ashrafizadeh, Zarrabi, Hashemi, et al., 2020b). For example, 
DOX- and edelfosine-loaded lipid-polymer hybrid nanostructures are 
able to mediate synergistic impact in suppressing chemoresistance 
feature of osteosarcoma (Yang, Zhang, et al., 2020). Besides, gold 
nanoparticle-mediated hyperthermia effectively kills colorectal cancer 
cells and increases their DOX sensitivity (Roma-Rodrigues et al., 2020). 
The present review aims to discuss the role of HA-modified nano-
architectures in the delivery of DOX, and exploitation of this strategy in 
improving current cancer chemotherapy. 
3.2. HA and DOX combination in synergistic cancer therapy 
For exerting its anti-tumor activity, a certain chemotherapeutic 
agent such as DOX should first penetrate into cancer cells and then, 
affect cytoplasmic organelles and make other alterations in nucleus, if 
necessary. However, there are receptors on cell membrane such as P- 
glycoprotein (P-gp) belonging to ATP-binding cassette (ABC) family, 
that can induce drug efflux, leading to chemoresistance (Liu, Bai, et al., 
2020; Liu et al., 2021). For overcoming DOX resistance, reducing ac-
tivity and expression of P-gp are of importance (Wang et al., 2021). 
Furthermore, cancer cells obtain resistance to DOX-mediated cell death 
(apoptosis). Therefore, conjugation or co-administration of DOX and 
anti-tumor agents can sensitize cancer cells to apoptosis, improving 
chemosensitivity (Yang, Li, et al., 2020; Zhong et al., 2020). In case of 
DOX and HA, just one experiment has highlighted role of this combi-
nation in synergistic cancer therapy and more studies are needed to 
evaluate role of HA and its derivatives in increasing DOX's anti-tumor 
activity and suppressing resistance. HA-curcumin conjugation can pro-
mote DOX sensitivity of lung, liver and intestinal cancers via mediating 
targeted delivery (CD44 receptor) and subsequent down-regulation of P- 
gp. Furthermore, HA-curcumin conjugation induces apoptosis via 
mitochondrial pathway in cancers (Diao et al., 2019). This experiment 
reveals that anti-apoptotic and regulatory impact of HA-curcumin 
conjugation on P-gp sensitize cancer cells to DOX chemotherapy. 
However, no certain and absolute conclusion can be made from one 
experiment and more studies are needed in this case. 
3.3. Role of HA-based nanoparticles in suppressing DOX resistance 
In the previous section, it was shown that HA-based advanced ma-
terials can be used to enhance the intracellular accumulation of DOX and 
increase its competence in cancer therapy; HA-based nanoscale delivery 
systems can be deployed to reverse the DOX resistance as their modifi-
cation with triphenylphosphonium (TPP) assists in targeting the mito-
chondria. However, DOX-TPP conjugate has an amphiphilic nature and 
so is difficult to encapsulate within nanocarriers. But the bromide salt of 
TPP can be used instead for linking to HA via ionic bonds to prepare a 
supra-molecular self-assembled structure comprising HA, DOX and TPP. 
These nanoparticles specifically targeted mitochondria to increase 
reactive oxygen species (ROS) levels and decrease mitochondrial 
membrane potential, resulting in the suppression of DOX resistance (Liu 
et al., 2018). This experiment highlights the fact that affecting mito-
chondria is of interest for activating intrinsic pathway of apoptosis in 
sensitizing cancer cells to death and suppressing DOX resistance. In 
order to obtain such potential, agents capable of targeting mitochondria 
such as TPP, as mentioned before, can be utilized. 
HA-based advanced materials can enhance tumor accumulation and 
improve the anti-tumor activity of DOX while reducing its adverse ef-
fects. HA modification significantly enhances the selective targeting of 
cancer cells and can be further improved using PEGylation to augment 
the enhanced permeability and retention (EPR) effect (Wang, Li, et al., 
2018). Enzymatic degradation of HA mediates the internalization and 
enhances the accumulation of DOX in colon cancer cells, leading to P-gp 
down-regulation and the reversal of DOX resistance (Yim & Na, 2010). 
In fact, the potential of HA-modified nanoparticles in reversing DOX 
resistance is attributed to targeting tumor-promoting factors such as P- 
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gp, Notch-1 signaling and anti-apoptotic proteins (Bcl-2). 
In vivo experiments have confirmed the efficacy of DOX-loaded HA 
nanocarriers in cancer therapy. Cross-linking HA with lipoic acid (LA)- 
lysine (Lys) led to the formation of nanoparticles with a size of 152–219 
nm. In vivo experiment in nude mice showed an enhanced circulation 
time of HA-LA-Lys nanoparticles and their accumulation at the tumor 
site, resulting in the increased anti-tumor activity of DOX and prevent-
ing DOX resistance (Zhong et al., 2015). To improve the stability and 
encapsulation efficiency of HA nanoparticles, other kinds of polymers 
have been used exemplified by the preparation of HA with vitamin E 
succinate co-polymers (HA-VES) that could be loaded with DOX. They 
demonstrated superior colloidal stability and high encapsulation effi-
ciency. HA-VES nanocarriers could release DOX into the lysosomes, 
enabling nuclear delivery, and promoting interactions with DNA, ulti-
mately leading to apoptosis and suppression of DOX resistance (Wang, 
Ma, et al., 2016). Overall, the following bullet points can be concluded: 
Fig. 1. Structure and occurrence of HA. A. The chemical structure of HA showing a polymer of disaccharides with a glycosidic bond linking the N-acetyl-D- 
glucosamine group with the D-glucuronic acid group. B. Common organs with high levels of HA. HA, hyaluronic acid. 
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Fig. 2. Different types of nano-sized structures containing a wide variety of cargos have been functionalized with hyaluronic acid to enhance the targeted delivery to 
tumors. NP: nanoparticle. 
Fig. 3. HA-modified polymeric NPs for DOX delivery. (A) Schematic illustration of polymeric nanoparticles and application in cancer therapy. (B) TEM image of the 
polymeric nanoparticles. (C) Schematic illustration of the procedures used to evaluate the phototherapeutic effect of polymeric nanoparticles towards 3D MCF-7 
spheroids. DOX: doxorubicin; IR780: near-infrared dye; HPN: hyaluronic acid polymeric nanoparticles. 
Reprinted from (Alves et al., 2019) with permission from Elsevier. 
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A) The HA-modified nanoparticles have confirmed their efficiency 
in overcoming DOX resistance in vitro and in vivo,  
B) These nanostructures possess high stability and biocompatibility, 
but stability can be further improved by conjugation with other 
agents such as VES, 
C) The role of HA-modified nanoparticles in reversing DOX resis-
tance depends on cargo delivery, so that co-delivery of DOX with 
miRNA-34a suppresses tumor-promoting Notch-1 signaling in 
inhibiting DOX resistance (Deng et al., 2014; Liu et al., 2019),  
D) Activation of apoptosis is a main pathway followed by HA- 
modified nanoparticles in reversing DOX resistance. 
4. Hyaluronic acid-modified nanomaterials 
Several nano-sized structures encompassing a wide variety of 
different cargos have been modified with HA, to improve their targeted 
delivery (Fig. 2). 
4.1. Polymeric nanoparticles 
4.1.1. Non-responsive polymeric nanoparticles 
Because DOX possesses several adverse effects that are dose- 
dependent, new approaches are required to reduce its toxicity on 
normal cells and tissues. The administration route can be a determining 
factor as the highest toxicity of DOX is observed with systemic admin-
istration. Consequently, there have been efforts to develop nanoparticles 
for the oral delivery of DOX and increasing its bioavailability and anti- 
tumor activity, while a simultaneous decrease in side effects is pro-
vided. Recently, catechol-modified CS/HA nanoparticles have been 
assessed for the topical delivery of DOX for oral cancer treatment; 
catechol and chitosan facilitated the adhesion of nanoparticles to the 
oral mucosa. The conjugation of HA and CS was performed using an ion 
gelation method to generate particles of 160 nm in size with a loading 
capacity as high as 250 mg/mg. These nanoparticles released DOX in a 
prolonged manner to enhance its cellular uptake, leading to the induc-
tion of apoptosis in cancer cells (Pornpitchanarong et al., 2020). 
Therefore, mucoadhesive polymers should be conjugated to DOX-loaded 
HA nanoparticles to make them appropriate for oral administration and 
enhancing DOX cytotoxicity in cancer treatment. 
In another study, PEGylated cationic amphiphilic copolymers were 
prepared and modified with HA to improve their biocompatibility and 
selectivity towards cancer cells. The DOX release of these nanoparticles 
occurred following the degradation of HA in endosomes by endogenous 
hyaluronidase, and subsequent PEG decomposition at the acidic pH of 
the endosome, resulting in DOX release and cytotoxicity against cancer 
cells (Fig. 3) (Yan et al., 2019). 
HA-based nanoparticles can be further modified to improve some of 
their properties, such as circulation time and cellular uptake. For 
instance, glycyrrhetinic acid (GA) was conjugated to the hydroxyl 
groups of HA to prepare DOX-loaded GA/HA-nanoparticles. These 
nanoparticles showed an increased circulation time in blood, good cell 
internalization, and specific targeting to the liver and were tested for the 
treatment of liver cancer (Wang, Gu, et al., 2018). Overall, HA- 
polymeric nanoparticles could be promising candidates for DOX de-
livery, while their toxicity towards normal cells and tendency to ag-
gregation remain as drawbacks (Oommen et al., 2016). However, these 
nanoparticles have obvious advantages such as high selectivity towards 
cancer cells, offering sustained release, and enhanced cellular uptake of 
DOX (Jin et al., 2015; Shahriari et al., 2019). Besides, HA-modified 
polymeric nanostructures potentiate DOX chemotherapy via increasing 
its intracellular accumulation and reducing IC50 (preventing develop-
ment of drug resistance after repeated administration). Although a 
number of studies have used other polymers such as CS and GA for 
promoting efficacy of HA nanoparticles in DOX delivery, a special 
attention should be directed towards biocompatibility of these agents. 
Furthermore, HA nanoparticles cause platelet aggregation at high doses 
that is a drawback for their clinical application. 
4.1.2. Stimuli-responsive polymeric nanoparticles 
The tumor microenvironment has a variety of features that differ 
significantly from normal tissues, an important one being its mild acidic 
pH (Garg et al., 2020; Moraes et al., 2017). Several anti-tumor drugs and 
compounds can be negatively affected by this microenvironment. For 
instance, the mild acidic pH may result in structural alterations in anti- 
tumor compounds and reduce their efficacy in cancer therapy. 
Furthermore, the genetic material and nucleic acids can undergo un-
expected changes when they are exposed to acidic conditions. Therefore, 
it is important to protect the normal cellular DNA against acidic 
microenvironment. Importantly, the acidic tumor microenvironment 
can be exploited to trigger the release of drugs from pH-responsive 
nanocarriers. 
Recently, spherical core-shell HA-based nanoparticles have been 
designed for the DOX delivery with a particle size in the range of 
167–220 nm. When modified with HA, they could selectively target 
CD44 overexpressing cells and enable the internalization of DOX in a 
receptor-dependent manner. Furthermore, these nanocarriers were pH- 
responsive, showing the preferential release of DOX at an acidic pH. Low 
toxicity towards normal cells (good biocompatibility) and cytotoxicity 
against cancer cells suggested that HA-based pH-responsive nano-
particles could be promising agents in cancer chemotherapy (Liao et al., 
2018). Some efforts have been made to improve the rate of endocytosis 
of HA nanoparticles to enhance the uptake into cancer cells. Significant 
efforts need to be made in reducing their particle size, as most of the HA- 
based nanostructure tend to have a particle size larger than 150 nm 
(Tian et al., 2019). 
Another strategy to develop smart HA nanoparticles for DOX de-
livery is to rely on changes in the redox balance. Disulfide-based proteins 
and small-molecule prodrugs have been synthesized whose release de-
pends on the intracellular GSH levels (Tjin et al., 2017) as their con-
centrations cause the cleavage of disulfide bonds. For this purpose, GSH- 
responsive HA nanoparticles containing DOX-D-alpha-tocopheryl poly-
ethylene glycol 1000 succinate (TPGS) conjugates as prodrugs have been 
developed. Disulfide bonds are formed between DOX and TPGS, and 
upon their targeted delivery by HA nanoparticles to tumors, the high 
GSH levels induce disulfide bond cleavage, leading to DOX release and 
enhancing anti-tumor activity. It is noteworthy that HA nanocarriers 
show an encapsulation efficiency as high as 90% (Lu et al., 2019). 
Macropinocytosis and clathrin-mediated endocytosis are the major 
pathways used by HA-based nanoparticles for uptake into the cancer 
cells. Redox-responsive HA nanostructures show a rapid release of DOX 
for cancer therapy. Furthermore, both in vitro and in vivo studies have 
confirmed the role of HA-nanoparticles in DOX delivery and cancer 
therapy (Hu et al., 2016). Due to the high biocompatibility of HA-based 
advanced nanomaterials, further developments are needed to expand 
their application into clinical trials. 
In addition to the development of smart HA nanoparticles based on 
internal stimuli such as pH and GSH, external stimuli can be used to 
trigger the DOX release which can provide superior spatiotemporal 
control over drug release. This approach can provide multiple dosages 
from a single administration of drug carrier which can improve patient 
satisfaction (Timko et al., 2010). Light responsive nanocarriers can be 
based on polymeric or lipid-based nanostructures (Bansal & Zhang, 
2014; Rwei et al., 2015), or inorganic nanoparticles (Huschka et al., 
2011; Zhang et al., 2016; Zhong et al., 2014). For instance, light- 
activated HA-based nanomaterials have been designed for DOX de-
livery. These degradable nanoparticles were responsive to either near- 
infrared (NIR) or ultraviolet (UV) radiation. The major component for 
synthesizing these nanogels was g-7-N, N-diethylamino-4-hydrox-
ymethylcoumarin (CM), and for enhancing their selectivity towards 
cancer cells, they were modified with HA. Exposing the HA-CM nanogels 
to either NIR or UV irradiation triggered the cleavage of the urethane 
bond linking HA to CM which subsequently released DOX and 
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suppressed the breast cancer progression. Because the breast cancer cells 
express higher levels of CD44, HA modification of nanogels led to their 
internalization via endocytosis (Hang et al., 2017). A wide variety of 
experiments have explored role of HA-modified polymeric nanoparticles 
and their advanced forms for DOX delivery. In order to be stimuli- 
responsive, a special linkage should be used to degrade by mild acidic 
pH, redox or light, leading to controlled release of DOX at tumor site. 
4.2. Carbon-based nanostructures 
The biomedical application of graphene oxide (GO) in cancer ther-
apy is of interest due to its high loading efficiency and hydrophilic 
oxygenated functional groups that are the key for the surface modifi-
cation via covalent and noncovalent bonds (Orecchioni et al., 2015; 
Yang et al., 2008; Zhu et al., 2010). In cancer therapy, GO nanoparticles 
have been applied for gene and drug delivery, theranostics, as well as 
photothermal and photodynamic therapy (Choi et al., 2016; Jung et al., 
2014; Lu et al., 2009; Tian et al., 2011; Yang et al., 2011). For DOX 
delivery, HA-Arg-Gly-Asp peptide (RGD)-modified GOs have been 
developed. These nanocarriers have a loading capacity as high as 72.9% 
and could release DOX in a sustained manner while still having good 
biocompatibility. Compared to DOX alone, DOX-loaded HA-RGD GO 
nanomaterials showed higher cytotoxicity in cancer cells due to their 
enhanced cellular uptake via CD44 receptor (HA) and integrin (RGD)- 
induced endocytosis (Guo et al., 2017). Another study prepared a 
composite of HA-based GO and iron oxide (IO) nanoparticles for DOX 
delivery and magnetothermal therapy. For this purpose, HA was con-
jugated to GO through covalent bonding, with good biocompatibility. 
DOX-loaded GO nanomaterials selectively killed CD44-overexpressing 
breast cancer cells. In the next step, IO nanoparticles were loaded on 
the GO nanoparticles to allow magnetic hyperthermia. This combination 
significantly enhanced the ability of DOX to reduce tumor growth and 
malignancy (Pramanik et al., 2019). To improve the biocompatibility of 
HA-based GOs, they can be additionally modified with CS (Yang et al., 
2016). Another advantage of nanocarriers is that they can be designed to 
respond to distinct properties of cancer cells, such as being pH- 
responsive. Furthermore, by enabling photothermal therapy, HA-based 
GO nanomaterials can enhance the efficacy of chemotherapy and syn-
ergistically increase cancer cell death (Liang et al., 2019; Miao et al., 
2013; Song et al., 2014). These experiments reveal a new advantageous 
of GO nanoparticles in DOX chemotherapy by providing photothermal 
therapy that can significantly promote its potential in cancer eradica-
tion. However, graphene-based nanomaterials suffer from low biocom-
patibility and introducing HA-modified graphene-based nanomaterials 
for DOX delivery in clinical course, depends on further modification, for 
instance by other biocompatible agents such as CS to improve their 
biocompatibility (Makvandi et al., 2020). Carbon dots (CDs) are newly 
emerging carbon nanomaterials with good biocompatibility and easy 
surface modification possibilities (Ashrafizadeh, Mohammadinejad, 
Kailasa, et al., 2020; Baker & Baker, 2010; Singh et al., 2017). CDs have 
been applied for gene and drug delivery in cancer therapy (Du et al., 
2019; MOHAMMADINEJAD et al., 2020; Panwar et al., 2019). However, 
it has been reported that unmodified CDs are not suitable to deliver 
cargos to tumor tissues. Therefore, studies have focused on the surface 
modification of CDs with various biocompatible agents (such as HA) to 
promote their selectivity towards cancer cells (Fu, Jang, et al., 2019; Xu 
et al., 2015). In a recent report, HA-functionalized CDs were prepared 
using a one-step hydrothermal treatment in the presence of citric acid 
and branched-PEI as the core carbon source. Then, DOX was loaded on 
the HA-modified CDs via acid-cleavable bonds and their cytotoxicity 
was evaluated against breast cancer cells wherein the in vitro and in vivo 
experiments confirmed the high anti-tumor activity of DOX-loaded HA- 
modified CDs (Li, Li, et al., 2020). Another study described the prepa-
ration of mesoporous silica nanoparticles (MSNs) coated with blue 
fluorescent N-graphene quantum dots, then loaded with DOX, and 
finally functionalized with HA. These theranostic nanocarriers enabled 
simultaneous cell imaging while increasing the potential of DOX in 
cancer cell killing lacking toxicity towards normal cells (Gui et al., 
2017). The advantages of CDs are their small size, good biocompati-
bility, and theranostic potential. However, GO nanomaterials demon-
strate some toxicity towards normal cells as shown in different 
experiments (Gurunathan et al., 2019; Karki et al., 2020; Mohamed 
et al., 2019). Further use of DOX-loaded HA-modified GO nanomaterials 
in clinical studies will depend on improved biocompatibility. One of the 
limitations is that in contrast to other kinds of nanocarriers, experiments 
have not prepared HA-modified carbon nanomaterials for DOX delivery, 
an aspect that can be further studied. 
4.3. Lipid-based nanoparticles 
4.3.1. Non-responsive lipid-based nanoparticles 
Liposomes and lipid nanocarriers are often employed in drug and 
gene delivery due to precise targeting of body organs or tumor sites, 
including the brain (Pinzón-Daza et al., 2013; Xie et al., 2005). The ef-
ficacy of liposomal nanocarriers can be improved by surface modifica-
tion and subsequent preferential cellular uptake through active or 
passive mechanisms (Gregoriadis, 1988; Iyer et al., 2006). Passive tumor 
targeting can be achieved via the EPR effect, and modification of the 
nanoparticles with ligands recognized by cancer cells can provide active 
targeting. For this purpose, HA-modified liposomal carriers have been 
developed for glioblastoma therapy; HA-based nanocarriers could spe-
cifically target glioblastoma cells, which over-expressed CD44 on their 
surface. Subsequently, lysosomal degradation allowed the intracellular 
delivery of DOX. Interestingly, normal astrocytes and microglial cells 
showed less co-localization of the nanocarriers in lysosomes suggesting 
good selectivity for tumor cells (Hayward et al., 2016). It was shown that 
the cytotoxicity of DOX-loaded liposomes towards normal cells 
decreased following the surface coating with HA-ceramide (HACE); 
HACE liposomes can be used for both imaging and drug delivery in 
cancer therapy. These liposomal carriers can serve as magnetic reso-
nance (MR) imaging probes when loaded with a suitable contrast agent. 
Besides, HACE-based liposomes released DOX in a sustained manner, 
with a longer circulation time in blood thus enhancing the anti-cancer 
effect (Park et al., 2014). Conventional DOX-loaded liposomes show 
some cardiotoxicity, and their modification with HA significantly 
improved their biocompatibility. Moreover, HACE conjugation made 
the liposomes pH-responsive which improved the capacity of targeting 
cancer cells (Paliwal et al., 2016). 
Micelles are another type of lipid-based nanocarrier with extensive 
applications in cancer therapy. Self-assembled polymeric micelles (PMs) 
are promising carriers for drug delivery due to their efficiency to 
encapsulate hydrophobic drugs and their superior tumor targeting ca-
pacity (Cabral et al., 2011; Jhaveri & Torchilin, 2014; Torchilin, 2007). 
Hydrophobic drugs can be loaded into the hydrophobic core of amphi-
philic micelles (Domb & Kumar, 2011; Hamaguchi et al., 2005; Matsu-
mura & Kataoka, 2009). Upon systemic administration, micelles owing 
to their small size can accumulate in tumor tissues with a neovascular 
capillary network (Maeda, 2010; Maeda & Matsumura, 2011; Matsu-
mura & Maeda, 1986). A study described the preparation of bioreducible 
core cross-linked HA micelles using D,L-dithiothreitol in aqueous con-
ditions to form disulfide bonds. These PMs displayed high structural 
stability and good encapsulation efficiency (80%). Due to their stability 
in the bloodstream, the HA-based micelles accumulated in the tumor site 
to promote the internalization of DOX. The release of DOX was depen-
dent on glutathione (GSH) levels, as the higher levels of GSH cleaved the 
disulfide bonds to trigger DOX release (Han et al., 2015). Another study 
described the conjugation of DOX to a short peptide, known as 
KIGLFRWR with a self-assembly prowess. Then, to enhance the targeting 
capacity of these nanoparticles, they were modified with HA. The core- 
shell structure of the micelles significantly promoted the internalization 
of DOX in hepatocellular carcinoma cells to suppress their proliferation 
(Wang, Qian, et al., 2020). HA lipid nanoparticles can enhance cellular 
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uptake of DOX by targeting CD44-overexpressing cancer cells. Conju-
gation with baicalein, a natural anti-tumor flavonoid, provided a syn-
ergistic effect and led to the effective eradication of breast cancer cells 
(Liu et al., 2016). This experiment highlighted the fact that phyto-
chemicals with anti-tumor activity (baicalein) can be loaded in HA- 
modified lipid nanoparticles to potentiate anti-tumor activity of DOX. 
Next experiments can focus on delivery of DOX with other plant derived- 
natural compounds such as curcumin, resveratrol and berberine using 
HA-modified lipid nanoparticles. 
There are many advantages associated with the use of HA-based lipid 
nanocarriers for DOX delivery, including enhancing cellular uptake 
through receptor-mediated endocytosis, promoting DOX bioavailability 
by overcoming the hydrophobic nature of DOX, preventing drug resis-
tance, and reducing the DOX side effects. Further improvements in the 
synthesis of smart HA-lipid nanocarriers are continuously being made to 
enhance the cytotoxicity against cancer cells (Arpicco et al., 2020; Chiu 
et al., 2020; Duan et al., 2020; Liu et al., 2019; Pornpitchanarong et al., 
2020; Wang, Qian, et al., 2020; Xu et al., 2021; Zheng et al., 2017). 
Table 1 summarizes assorted HA-based nanomaterials that have been 
deployed for DOX delivery in cancer therapy. 
4.3.2. Stimuli-responsive lipid-based nanoparticles 
HA-modified nanoparticles can release DOX in a mildly acidic pH 
(5.0) in a sustained-release manner (Gurav et al., 2016). One strategy 
uses covalent conjugation for the formation of Schiff base bonds be-
tween DOX and HA in nanostructures. DOX has a hydrophobic nature 
and is loaded into the hydrophobic core, while HA being a hydrophilic 
compound used as the shell. The DOX release from pH-responsive 
nanocarriers occurred at pH 5.0 with only minimal release at pH 7.4, 
affirming the ability of HA-based advanced materials to transport DOX 
for cancer therapy (Hu et al., 2017). 
Other experiments have applied a redox-responsive HA-ibuprofen 
prodrug containing micelles for DOX delivery to treat metastatic breast 
cancer. The HA-ibuprofen conjugate is sensitive to a reducing environ-
ment and the conjugation was performed by attaching ibuprofen to an 
HA backbone through disulfide bonds. This prodrug could self-assemble 
into micelles and showed advantages including high cellular uptake, 
good biodistribution and was responsive to redox stimulus (Chai et al., 
2020). HA nanoparticles can be designed so they are dually responsive 
to both GSH and pH. Recently, self-assembled micelles were developed 
by HA-6-mercaptopurine (MP) conjugation; MP has a hydrophobic na-
ture, while HA is hydrophilic. DOX was loaded into the core of the 
nanocarriers, and the activity against cancer cells and cancer stem cells 
(CSCs) was evaluated. HA nanoparticles were internalized in a CD44- 
dependent manner as a CD44-antibody prevented their internalization. 
The HA nanoparticles induced cell cycle at the G0/G1 phase in colon 
cancer cells. Due to their GSH-responsive and pH-responsive nature, HA 
nanocarriers could significantly promote the DOX delivery for cancer 
therapy (Debele et al., 2018). However, we are still at the initial stages of 
developing smart nanocarriers for DOX delivery and more studies are 
needed before transitioning to clinical trials. The experiments have 
focused on developing smart HA-modified micelles for DOX delivery and 
more studies are required role of advanced HA-modified liposomes in 
DOX delivery. Then, a comparison between their potential in delivery 
and suppressing cancer progression can be made. 
4.4. Inorganic nanostructures 
4.4.1. Non-responsive inorganic nanoparticles 
Inorganic nanoparticles are promising candidates for the delivery of 
DOX as the surface modification of these nanocarriers can significantly 
improve their selectivity towards cancer cells. Recently, hybrid nano-
particles containing organic and inorganic materials have been devel-
oped for DOX delivery. Metal-organic frameworks (MOFs) have 
Table 1 
HA-based nanomaterials for DOX delivery in cancer therapy.  
Nanovehicle Cancer type Particle size (nm) 








Breast cancer 153.1 nm 
− 9.3 mV 
Hyaluronic acid Improved cellular uptake of DOX by CD44-mediated 
endocytosis 
Suppressed cancer growth 
(Gupta et al., 2018) 
Mesoporous silica 
nanoparticles 
Breast cancer – Hyaluronic acid Excellent therapeutic potential 
Long blood circulation 
Accumulation at the tumor site 
(Zhan et al., 2021) 
Polymeric nanoparticles Breast cancer – Hyaluronic acid Exerted cytotoxicity against cancer cells 
Polarized macrophages 
Changed macrophage phenotype to M1 
(Rangasami et al., 
2021) 
Polymeric nanoparticles Breast cancer 264.5 nm 




Enhanced ROS levels 
Apoptosis induction 
Enhanced cellular accumulation 
(Kim et al., 2018) 
Protein nanoparticles Breast cancer 132 nm 
− 38.9 mV 
43.2% 
Hyaluronic acid Cellular uptake through CD44-mediated endocytosis 
Simultaneous imaging and chemotherapy 







− 20.8 mV 
Hyaluronic acid HA functionalization improved selectivity towards cancer 
cells 
Suppressed colorectal cancer progression 
(Wan et al., 2016) 
Polymersomes Breast cancer 146.2 nm 
54.9% 
Hyaluronic acid Excellent biodistribution 
High anti-tumor activity 
(Shahriari et al., 
2019) 
Iron nanoparticles Breast cancer 210.3 nm 
− 24 mV 
Hyaluronic acid Enhanced tumor targeting capacity of nanocarriers 
Eradicated cancer cells and cancer-associated fibroblasts 
Sustained circulation and high cellular uptake 
Enhanced potential of DOX in cancer therapy 
(Gong et al., 2019) 
MOF‑iron nanoparticles Breast cancer 140 nm 
− 25 mV 
Hyaluronic acid Disrupted iron homeostasis in cancer cells 
Sensitized cell death 
Ferroptosis induction 
Increased potential of DOX in cancer eradication 
(Xu et al., 2020) 
Iron nanoparticles Breast cancer 48.2 nm 
− 45 mV 
Lipid 
Hyaluronic acid 
Due to high cellular uptake, DOX effectively suppressed 
the progression of cancer cells 
(Liang et al., 2020) 
Gold nanorods Breast cancer 55 nm 
− 35.6 mV 
Hyaluronic acid Simultaneous chemotherapy and photothermal therapy 
Efficiently suppressed tumor growth 
(Li, Duy Le, et al., 
2019)  
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Table 2 
Smart HA-based nanomaterials for DOX delivery in cancer therapy.  










HA-based micelles Reduction- 
sensitive 
Lung cancer 259.6 nm 





Enhanced cellular uptake due to 
CD44-mediated endocytosis 
Increased chemotherapy efficacy 
(Debele 
et al., 2018) 
Hollow-mesoporous 
silica nanoparticles 
Redox-responsive Breast cancer 232 nm 
− 23.9 mV 
Doxorubicin Hyaluronic 
acid 
Suppressed tumor proliferation 
Apoptosis induction 









Reduced cell viability as much as 80% 
Inhibited tumor growth 
(Lu et al., 
2019) 
Liposomes Redox-responsive Osteosarcoma 165.3 nm 




Burst release of DOX (60%) in the 
presence of GSH 
Long blood circulation 
Cytoplasmic delivery of cargo 
(Chi et al., 
2017) 
Micelles Redox-responsive Breast cancer 170 nm 






Favorable anti-tumor activity 
On-demand release of drug 
(Chai et al., 
2020) 
Gold nanorods Redox-responsive Breast cancer 214–433 nm 





Reduced drug efflux 
Increased cellular uptake 




Redox- and pH- 
dual responsive 
Breast cancer 140–190 nm 
− 15 mV 
Doxorubicin Hyaluronic 
acid 
Mildly acidic pH or high GSH 
conditions induced DOX release 
High targetability 
Enhanced anti-tumor activity 
(Lu, Xiao, 
et al., 2020) 
Mesoporous silica 
nanoparticles 




110 nm Doxorubicin Hyaluronic 
acid 
Controlled release of cargo in 
reducing and acidic conditions 
High cellular uptake 
Inhibited cancer progression 
(Lin et al., 
2017) 
Carbon dots Redox- and 
enzyme-dual 
responsive 
Lung cancer 230 nm 





High biocompatibility and excellent 
fluorescence 
Enhanced cellular uptake in lung 
cancer cells through CD44-mediated 
endocytosis 
Dual-stimuli responsive with 
simultaneous imaging capability 




Redox- and pH- 
dual responsive 
Breast cancer 100 nm 





High cell targeting capability 
(Lu, Xiao, 
et al., 2020) 
Micelles Redox- and pH- 
sensitive 
Lung cancer 188.4 nm 
− 17.54 mV 
Doxorubicin Hyaluronic 
acid 
Rapid DOX release in reducing or low 
pH conditions 
Receptor-mediated endocytosis 
Apoptosis induction and high 
cytotoxicity against cancer cells 
(Yin et al., 
2018) 














pH-sensitive Breast cancer 30–50 nm Doxorubicin Hyaluronic 
acid 
Increased circulation time by 12.5 
fold 
Selective targeting of cancer cells 
High anti-tumor activity against 
cancer cells 
(Zhang, 











Cancer cell internalization by binding 
to CD44 receptors 
Inhibited cancer growth 
Promoted DOX cytotoxicity against 
cancer cells 
(Wang, Tian, 






− 16.8 mV 
Doxorubicin Hyaluronic 
acid 





et al., 2018) 
Polymeric 
nanoparticles 
Light-responsive Breast cancer 90–272 nm 
− 3.62 to − 5.89 
mV 
Up to 82.6% 
Doxorubicin Hyaluronic 
acid 
Provided deep penetration into 
tumors 
Well-tolerated 
Inhibited tumor growth 
Synergistic effect between 
photochemical internalization and 
doxorubicin 
(Ji et al., 
2019) 
Gold nanoparticles pH and NIR- 
responsive 
Breast cancer 70.9 nm 




chemotherapy and photothermal 
therapy 
(Xu et al., 
2017) 
(continued on next page) 
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potential biomedical applications in bioimaging, chemotherapy, 
photodynamic and photothermal therapy (Guo et al., 2018; Horcajada 
et al., 2010; Wu et al., 2018; Yao et al., 2019) as exemplified by MIL-100, 
a type of MOF, that has been utilized for drug delivery owing to its high 
drug loading capacity (Gupta et al., 2019). MIL-100 produced by 
microwave-assisted synthesis could be loaded with DOX. Further surface 
modification of the MOF nanoparticles with HA has been performed to 
provide tumor-targeted delivery. These nanoparticles could provide 
simultaneous chemotherapy and photodynamic therapy, leading to the 
increased anti-tumor activity of DOX (Xue et al., 2019). Super-
paramagnetic iron oxide nanoparticles (SPIONs) possess a variety of 
beneficial attributes, such as biocompatibility, large surface area and 
magnetic characteristics (Heydari Sheikh Hossein et al., 2020; Lee et al., 
2015; Reddy et al., 2012; Zafar et al., 2014) and they can be directed 
towards target sites by the application of external magnetic fields 
(López-Viota et al., 2017). The agglomeration and clearance of SPIONs 
from the blood circulation can be reduced by appropriate surface 
modifications (Akbarzadeh et al., 2012; Muthiah et al., 2013; Patsula 
et al., 2019). Their modification with HA improved the biocompatibility 
while reducing the uptake by macrophages (Fang et al., 2019; Ting Gong 
et al., 2019). Furthermore, lipid/HA-coated DOX-Fe3O4 nanoparticles 
demonstrated a high cellular uptake by endocytosis (Curk et al., 2017; 
Gupta et al., 2018). In one study, lipid/HA-coated DOX-Fe3O4 nano-
particles were assessed in cancer therapy where these nanocarriers with 
an average size of 48.2 nm could easily be taken up into breast cancer 
cells through endocytosis. In vitro and in vivo studies demonstrated the 
high tumor-specificity of these nanocarriers and their capacity to sup-
press growth and viability (Liang et al., 2020). This enhanced cytotox-
icity of DOX against cancer cells was due to the targeted delivery and 
enhanced cellular uptake provided by HA-based nanomaterials. 
As mentioned earlier, one of the benefits of surface modification of 
inorganic materials with HA is avoiding uptake by macrophages which 
are key players in the tumor microenvironment and their presence with 
an anti-inflammatory M2 phenotype increases the malignancy and sur-
vival of cancer cells (Mantovani et al., 2017; Qian & Pollard, 2010). It 
has been reported that surface modification of DOX-loaded Fe3O4 
nanocarriers with HA enhanced their selectivity towards tumor- 
associated macrophages. The killing of M2 macrophages increased the 
Table 2 (continued ) 











High intracellular accumulation 













Increased efficacy of DOX in cancer 
chemotherapy plus photothermal 
therapy 
CD44 and integrin-mediated 
endocytosis in cancer cells 
(Zhou et al., 
2017)  
Fig. 4. Doxorubicin-encapsulated nanocarriers functionalized with hyaluronic acid. (A) Schematic of the preparation procedure. (B) TEM image of the particles. (C) 
Cumulative release profiles of doxorubicin from the nanocarriers under neutral and acidic conditions. 
Reprinted from (Kong et al., 2016) with permission from Royal Society of Chemistry. 
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proportion of anti-tumor M1 polarized macrophages and promoted the 
anti-tumor immunity against breast cancer cells (Gong et al., 2019). HA- 
coated inorganic nanomaterials can improve the cytotoxicity of DOX 
against cancer cells and more studies are justified to realize their full 
potential (Cai et al., 2016). 
4.4.2. Stimuli-responsive inorganic nanoparticles 
Light-induced hyperthermia is another promising strategy for 
enhancing the cytotoxicity and therapeutic efficacy of chemotherapeutic 
agents (Podolska et al., 2020). HA‑gold nanorods were designed for DOX 
delivery. They were redox-responsive because of the cystamine use as a 
crosslinker and were degraded at high GSH concentrations. NIR light- 
induced hyperthermia, caused by energy absorption by the gold nano-
rods, suppressed the DOX resistance (Li, Xu, et al., 2019). Even though 
there are few potential strategies for DOX release, additional studies are 
required to extend the use of smart HA nanocarriers for DOX delivery in 
clinical settings (Table 2) (Alves et al., 2019; Debele et al., 2018; Hang 
et al., 2017; Hu et al., 2016; Hu et al., 2017; Jeong et al., 2019; Lee et al., 
2020; Liao et al., 2018; Liu, Li, et al., 2020; Mao et al., 2019; Palani-
kumar et al., 2018; Poudel et al., 2020; Shin et al., 2019; Sun et al., 2019; 
Wu et al., 2019; Yang et al., 2017; Yu et al., 2020; Zhang et al., 2018). 
Fig. 5 illustrates the use of smart HA-based materials for DOX delivery in 
cancer treatment. The following key points can be concluded (Fig. 4):  
A) Among different kinds of nanoparticles, a special attention has 
been directed towards surface modification of polymeric nano-
particles with HA for improving their characteristics,  
B) In addition to polymeric nanoparticles, lipid-based nanocarriers, 
inorganic materials and carbon-based nanostructures have been 
modified by HA in increasing delivery of DOX to cancer cells 
(Poudel et al., 2020),  
C) There is no study evaluating role of smart HA-modified carbon- 
based nanocarriers for DOX delivery and cancer treatment. In 
terms of capacity of CDs in bioimaging and their application as 
diagnostic factors, it would be beneficial to develop advanced 
HA-modified CDs for DOX delivery and simultaneously, trace 
response of cancer cells. 
5. Hyaluronic acid for co-delivery of drugs or genes along with 
DOX 
5.1. Co-delivery of drugs and DOX 
Among the strategies to overcome DOX resistance, the combination 
of DOX with other anti-tumor compounds has prominence as they 
sensitize the cancer cells to chemotherapy (Guo et al., 2020; Halim et al., 
2019; Sabzi et al., 2020; Varughese et al., 2019). However, the other 
anti-tumor compounds may still have their drawbacks. For instance, the 
use of anti-tumor drugs such as cisplatin (CP) eventually leads to the 
induction of resistance, and deployment of naturally occurring anti- 
tumor compounds, such as curcumin, quercetin or resveratrol, have 
limitations because of poor bioavailability (Algahtani et al., 2020; 
Hussain et al., 2021; Ma et al., 2020; Mirzaei, Hushmandi, et al., 2021). 
HA-based nanocarriers can provide a platform for the co-delivery of 
DOX along with other anti-tumor compounds for more effective cancer 
therapy. In this section, we provide a mechanistic discussion on the use 
of HA-based nanoscale delivery systems for DOX and other anti-tumor 
compounds. 
Fig. 5. Smart HA-based nanoarchitectures for DOX delivery in cancer therapy. These nanoparticles are taken up into cancer cells through endocytosis, leading to 
enhanced cellular uptake of DOX. Further modifications can provide stimulus-responsive release of DOX such as changes in GSH levels, pH values, and light acti-
vation. HA, hyaluronic acid; DOX, doxorubicin, GSH, glutathione. 
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Fig. 6. (A) Preparation of HA-modified nanoparticles for co-delivery of DOX and CDDP; (B) Apoptotic effect of MCF-7 cells treated with PBS (a), free DOX (b), free 
CDDP (c), NP(DOX) (d), NPHER2(DOX) (e) and NPHER2(DOX/CDDP) (f). The lower left, lower right, upper right and upper left quadrants in each flow cytometric 
sorting profile present the percentages of living, early apoptotic, late apoptotic and necrotic cells, respectively. 
Reprinted with permission from (Wang, Qian, et al., 2019) from Elsevier. 
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Fig. 7. (A) Preparation of charge reversible HA-modified dendrimer micelles; (B) Cytotoxicity of Dox-loaded MDM, HA-DOPE/MDM-loaded with Dox and HA-DOPE/ 
MDM-loaded with Dox and 100 nM of siMDR-1 in (a) MDA-MB-231; (b) A2780 ADR; (c) HCT 116 cells compared with cells treated with BHG. Results indicate mean 
± SD, n = 3. ***p ≤ 0.001, **p ≤ 0.01, *p ≤ 0.05. 
Reprinted with permission from (Zhang, Pan, et al., 2020) from Elsevier. 
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CSCs play a significant role in cancer progression and metastasis, and 
therefore targeting of CSCs is the key in cancer eradication (Bhuvana-
lakshmi et al., 2018; Ma et al., 2019; Najafi et al., 2019). Anti-tumor 
compounds can be designed to be co-administered with DOX to target 
CSCs. Cyclopamine is a steroid alkaloid that acts as an inhibitor of CSCs 
and an amphiphilic nanocarrier was designed for the co-delivery of DOX 
and cyclopamine. The nanocarrier comprised hydrophobic PLGA as a 
head group and a hydrophilic HA segment connected by a bio-reducible 
disulfide bond. Because of the HA groups, these carriers could effectively 
target CD44 over-expressed on breast CSCs, and because of the bio-
reducible linkage, they responded well to the redox environment. 
Compared to monotherapy, this combination remarkably reduced the 
size and spheroid formation of CSCs and inhibited the breast cancer 
growth as confirmed by in vitro and in vivo experiments (Hu et al., 
2015). Various kinds of HA-based nanostructures can be synthesized for 
the delivery of DOX and other anti-tumor compounds. It has been re-
ported that HA conjugates can be loaded with and release another anti- 
tumor compound apart from DOX. For instance, gemcitabine (GEM) was 
released faster than DOX and had a higher efficacy compared to other 
types of HA conjugates (Vogus et al., 2017). 
Plant derived-natural compounds are also promising candidates for 
co-delivery with DOX due to their ability to target various molecular 
pathways responsible for cancer growth (Aziz et al., 2021; Chaitanya 
et al., 2021; Kashyap et al., 2019; Sethi et al., 2018; Shanmugam et al., 
2017). Modification of lipid carriers with HA can promote their selec-
tivity towards lung cancer cells. Loading DOX and baicalein on HA- 
modified lipid carriers promoted their cellular uptake and showed a 
synergistic effect between baicalein and DOX to effectively eradicate 
lung cancer cells (Liu et al., 2016). The same strategy was applied for the 
co-delivery of HA with quercetin or gallic acid, among other naturally 
occurring anti-tumor compounds. These compounds can increase the 
anti-tumor activity of DOX by inducing apoptosis and inhibiting tumor 
growth. HA-based nanocarriers can provide a platform for the co- 
delivery of DOX along with natural compounds and enhance their 
cellular uptake (Liu, Li, et al., 2020; Shao et al., 2019). Although these 
experiments have focused on augmenting anti-tumor activity of DOX, it 
is quite clear that combination cancer therapy with DOX and anti-tumor 
agents prevents development of drug resistance and the role of HA- 
modified nanoparticles is to provide a platform for their co-delivery. 
Overall, the use of HA-based nanomaterials enhanced the intracellular 
accumulation of DOX and the additional anti-tumor compounds, and 
provided the synergistic benefits that could be key in increasing the 
potential of DOX for cancer therapy and preventing the development of 
resistance (Fig. 6) (Lee et al., 2020). 
5.2. Co-delivery of genes along with DOX 
Another possibility to overcome DOX resistance is the deployment of 
nucleic acid genetic-based approaches wherein small interfering RNA 
(siRNA) and CRISPR/Cas9 systems have been utilized for down- 
regulating the genes that are involved in chemoresistance (Ashrafiza-
deh, Hushmandi, Hashemi, et al., 2020; Ashrafizadeh, Hushmandi, 
Rahmani Moghadam, et al., 2020; Li, Tan, et al., 2020; Xing & Meng, 
2020). However, there is still room for improving the efficiency of ge-
netic tools in cancer therapy. For instance, gene therapy suffers from 
several off-target effects and displays instability. Moreover, RNA-based 
approaches namely siRNA or microRNAs can be quickly degraded by 
RNase enzymes when circulating in the bloodstream (Mirzaei, Gholami, 
et al., 2021; Mirzaei, Mahabady, et al., 2021; Zhupanyn et al., 2020; Zou 
et al., 2020). Therefore, nanocarriers could be promising alternatives to 
Fig. 8. HA-based nanovehicles increase cell uptake of DOX, induce cell death by increasing ROS levels, mediating mitochondrial dysfunction, and causing DNA 
damage. HA, hyaluronic acid; DOX, doxorubicin; ROS, reactive oxygen species. 
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increase the efficacy of gene therapy (Delfi et al., 2021). In this section, 
some HA-based nanoparticles that have been developed for the co- 
delivery of DOX along with other nucleic acid-based tools, are discussed. 
MicroRNAs (miRNAs) are endogenous, short single-stranded RNA 
molecules with a length of 19–24 nucleotides (Ashrafizadeh, Ang, 
Moghadam, et al., 2020; Ashrafizadeh, Hushmandi, Hashemi, et al., 
2020; Ashrafizadeh, Hushmandi, Rahmani Moghadam, et al., 2020; 
Welponer et al., 2020). MiRNA dysregulation often occurs in cancer 
cells, and the expression of many tumor-suppressor miRNAs is lower, 
thus encouraging cancer progression (Hong et al., 2020; Mirzaei, Zar-
rabi, et al., 2021). One potential strategy is to supplant the low 
expressed miRNAs by delivering them using nanoparticles. HA-coated 
PEI-PLGA nanostructures were developed for the co-delivery of DOX 
and miRNA-542-3p to treat triple-negative breast cancer. In addition to 
suitable particle size (131.7 nm), the nanoparticles demonstrated high 
drug encapsulation efficiency (DOX) and inhibited the degradation of 
miRNA in serum. MDA-MB-231 cells expressing high levels of CD44 
were targeted by the HA-coated nanoparticles. Both, the DOX and 
miRNA-542-3p were internalized and inhibited the breast cancer cells 
by triggering apoptosis, up-regulation of p53 and down-regulation of 
survivin (Wang, Zhang, et al., 2016). Compared to lipofectamine applied 
for miRNA transfection, HA-modified nanoparticles demonstrate more 
capacity in enhancing expression level. However, it should be noted that 
high expression level of miRNA may be toxic for normal cells. Therefore, 
a rational increase should be made in miRNA expression (Fu, Peng, 
et al., 2019). 
SiRNA can reduce the expression of target genes, leading to down- 
regulation of the expression of tumor-promoting proteins, and sup-
pressing the cancer progression (Akbaba et al., 2020; Ashrafizade et al., 
2021; Ashrafizadeh, Zarrabi, Hushmandi, et al., 2020). SiRNAs are also a 
potential tool to improve the chemosensitivity in cancer cells (Joshi 
et al., 2020). Recently, HA-based dendrimeric nanocarriers were pre-
pared for the co-delivery of DOX along with siRNA-MDR-1. HA was used 
to coat the nanocarriers to shield the positive charges and promote the 
selectivity towards cancer cells overexpressing CD44. Additionally, the 
HA-based nanoparticles protected the siRNA against RNase-mediated 
degradation and increased its stability. Because the HA coating shiel-
ded the positive charges, the biocompatibility improved significantly. 
The high specificity and cellular uptake of DOX and siRNA led to 
effective cancer treatment and reduced drug resistance (Table 3, Fig. 7) 
(Zhang, Pan, et al., 2020). These studies showed that HA not only could 
improve the targeting and specificity of the nanoparticles but also pro-
tected the nucleic acids against degradation in vivo. This makes them 
suitable for further investigations in clinical settings. Fig. 8 provides an 
overview of the anti-cancer activity of HA-coated DOX-loaded 
nanocarriers. 
6. Theranostic applications 
HA-based nanoparticles can be utilized as theranostic agents in 
cancer therapy, providing simultaneous imaging and drug delivery. 
Recently, a conjugate of DOX-HA-methotrexate (MTX) was prepared as a 
prodrug for theranostic applications where DOX-MTX was attached to 
the HA backbone. To provide image-guided delivery, indocyanine green 
was used for fluorescence imaging. These nanocarriers had a variety of 
advantages including suitable particle size (200 nm), high physiological 
stability and effective photothermal capability. Due to the EPR- 
mediated tumor accumulation, and uptake into cancer cells through 
Table 3 
HA-functionalized materials in the co-delivery of DOX with other anti-tumor compounds or nucleic acids.  
Nanovehicle Cancer type Anti-tumor 
compound 
Gene Particle size (nm) 











Increased potential of DOX in cancer 
chemotherapy 
Lengthened blood circulation 
High cellular uptake 
Enabled DOX to access the nucleus 
(Han et al., 2012) 
Magnetic polydopamine 
nanoparticles 
Cervical cancer Doxorubicin 
Methotrexate 
– 236.5 nm 
− 22.5 mV 
Enabled simultaneous chemotherapy and 
photothermal therapy 
Selectivity towards cancer cells due to surface 
modification by HA 
Enhancing DOX accumulation in cancer cells 
(Li et al., 2018) 




– 200 nm 
− 23.97 mV 
Theranostics and image-guided delivery 
Increased cellular uptake 
Deep tumor penetration 
Uptake by endocytosis 
Combined chemotherapy and photothermal 
therapy 
(Chen, Chen, 
et al., 2019) 




– – Suppressed aggressive and malignant 
behavior 
Inhibited tumor growth in vivo after 
intravenous and subcutaneous injection 
(Vogus et al., 
2017) 
Polymeric nanoparticles Breast cancer Doxorubicin 
Cisplatin 
– 160 nm 
− 28 mV 
HER2-mediated cellular uptake 
Synergistic anti-cancer effects between DOX 
and cisplatin 
(Varughese et al., 
2019) 
Dendrimer nanoparticles Different cancers Doxorubicin siRNA- 
MDR-1 
225 nm 
− 18 mV 
HA coating shielded positive charge of 
PAMAM nanocarriers 
Enhanced cellular uptake 
Reduced cytotoxicity against normal cells 
High stability 
Synergistic effects in suppressing cancer 
progression 
(Zhang, Pan, 
et al., 2020) 
Lipid nanoparticles Breast cancer Doxorubicin 
Baicalein 




Exerted synergistic effects 
Suppressed cancer growth and viability 
(Liu et al., 2016)  
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CD44-mediated endocytosis, the DOX-MTX-HA displayed a higher 
accumulation at the tumor site. HA-based nanocarriers induced 
apoptosis and inhibited tumor growth as NIR irradiation caused an in-
crease in temperature and the resulting hyperthermia increased the ef-
ficacy of chemotherapy (Chen, Chen, et al., 2019). Theranostic 
applications of HA-based nanocarriers can be achieved by incorporating 
an imaging agent. Modification of graphene with HA and rhodamine B 
isothiocyanate (RBITC) produced dual-functional nanocarriers capable 
of targeted delivery of DOX and offered simultaneous imaging. DOX was 
loaded into the surface of HA/RBITC-graphene nanomaterials through 
π-π stacking, and as the fluorescence emission of the nanocarriers was 
quenched after DOX release, the fluorescence of the nanocarriers was 
recovered thus allowing imaging to be carried out; modification by HA 
enabled higher cellular uptake of DOX in cancer cells (Luo et al., 2016). 
As mentioned above, these HA-based theranostic agents can be activated 
by light, leading to simultaneous chemotherapy (DOX) and photo-
thermal therapy (Khatun et al., 2015). As minimally invasive imaging 
and therapy are of importance in clinic for treatment of cancer patients, 
more experiments are required to reveal true potential of DOX-loaded 
HA-modified nanocarriers as theranostic. 
7. Conclusions and remarks 
In the present review, we have discussed the applications of HA- 
based nanoparticles as promising agents for the delivery of DOX to 
improve cancer chemotherapy. HA can enhance the targeted delivery of 
nanocarriers by allowing CD44-mediated endocytosis and subsequently, 
increase the DOX uptake into cancer cells. HA nanomaterials could solve 
some challenges faced in DOX chemotherapy by overcoming drug 
resistance and reducing the side effects. Lipid, polymeric, carbon-based, 
and metal nanoparticles have been modified with HA to increase the 
intracellular accumulation of DOX in cancer cells. As HA is a naturally 
occurring compound, the use of this polysaccharide to coat nano-
particles increases their biocompatibility that is of importance for 
further clinical application. Smart HA-based delivery systems can be 
designed to be responsive to internal stimuli such as pH or redox and to 
external stimuli such as NIR or UV radiation. Smart nanocarriers take 
advantage of distinct properties of the tumor microenvironment, such as 
mild acidic pH or high GSH concentrations to release DOX at the tumor 
site and promoting its cellular uptake. Additionally, light-responsive HA 
nanoarchitectures can enhance the potential of DOX in cancer chemo-
therapy by mediating photothermal therapy, a strategy that is also 
beneficial in preventing DOX resistance in cancer cells. 
To increase the efficiency of DOX in cancer therapy, it can be com-
bined with other anti-tumor compounds or various nucleic acid-based 
types of gene therapy. The ideal pathway to perform these kinds of 
combination therapies is to load both components into a single nano-
carrier. HA-based delivery systems can provide a platform for the co- 
delivery of drugs or genes combined with DOX. Gene therapy with 
siRNA or miRNA can up-regulate tumor-suppressing factors or down- 
regulate tumor-promoting factors, thereby increasing the sensitivity of 
cancer cells to DOX. Not only can HA nanoparticles mediate the targeted 
delivery of nucleic acids, but they can also protect them against degra-
dation in the biological environments. A newly emerging application of 
HA nanoparticles is in theranostics, allowing simultaneous imaging and 
therapy. When HA nanomaterials are used as theranostic agents, fluo-
rescent dyes such as indocyanine green or RBITC are utilized to enable 
image-guided delivery of DOX to the tumors. 
Although we have described the potential role of DOX-loaded HA 
nanoparticles in cancer therapy, the experiments described so far have 
been limited to pre-clinical studies (in vitro and in vivo). Because of the 
high biocompatibility of HA nanoparticles, further efforts should be 
made for their large-scale optimization, production, quality control, and 
testing in cancer patients to promote the efficacy of DOX in chemo-
therapy. Another limitation that can be explored is related to large-scale 
production of HA-modified nanoparticles for DOX delivery that requires 
an efficient method. 
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